ArticleJournal of neuro-oncology2025
Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeHigh-grade gliomas (HGGs) in children and adolescents/young adults (AYAs) are aggressive tumors with a poor prognosis. A subset is driven by constitutional mismatch repair deficiency (CMMRD), an inherited cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. Despite its clinical relevance, data on MMR deficiency (MMR-D) in Indian populations are scarce.
methodsWe retrospectively analyzed 100 cases of CNS WHO grade 4 diffuse HGGs (2016–2024) from a tertiary care center in North India. MMR protein expression was assessed by immunohistochemistry (IHC). With selected MMR-D cases further analyzed by Whole-exome sequencing (WES), tumor mutational burden (TMB), mutational signatures, and genome-wide methylation profiling. Immune markers, including PD-L1, CTLA-4, CD8, and p53, were also evaluated.
resultsComplete loss of at least one MMR protein was observed in 11% (11/100) cases, while another 5% (5/100) of cases showed partial loss PMS2 was the most frequently lost protein (62.5%), followed by MSH2, MLH1, and MSH6. Among MMR-D cases, 56.25% were pediatric and 43.75% were AYA, with median ages of 8 and 26 years, respectively. A significant correlation was found between the presence of giant cells and MMR status. WES revealed ultra-hypermutation (TMB > 100 mutations/Mb) in 4/6 tested cases and polymerase (POLE)-associated signatures in 66%. Concurrent mutations in TP53, NF1, and ATRX were frequently observed. Despite high TMB, PD-L1, CTLA-4, and CD8 expression showed no significant association with MMR status
conclusionOur study identified a 11% prevalence of MMR-D in CNS WHO grade 4 HGGs using IHC, with hypermutation predominantly driven by sequential MMR and polymerase pathway defects. These tumors exhibit unique molecular profiles distinct from adult sporadic gliomas and warrant routine MMR testing in pediatric and AYA patients for accurate diagnosis, genetic counseling, and consideration of immunotherapy.
Indexed as
Identifiers
41094292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.